Anixa Biosciences, Inc.
ANIX
$3.09
-$0.17-5.22%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -10.83% | -8.37% | -5.55% | -0.76% | 18.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.40% | -12.62% | 1.33% | 10.87% | 23.26% |
| Operating Income | 15.40% | 12.62% | -1.33% | -12.80% | -25.61% |
| Income Before Tax | 13.15% | 10.29% | -4.39% | -16.15% | -27.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.15% | 10.29% | -4.39% | -16.15% | -27.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -29.86% | -28.28% | -16.67% | 13.11% | 21.01% |
| Net Income | 12.96% | 10.08% | -4.65% | -16.19% | -27.96% |
| EBIT | 15.40% | 12.62% | -1.33% | -12.80% | -25.61% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 14.45% | 11.78% | -2.11% | -12.75% | -24.31% |
| Normalized Basic EPS | 14.32% | 11.67% | -2.31% | -12.79% | -24.44% |
| EPS Diluted | 14.45% | 11.78% | -2.11% | -12.75% | -24.31% |
| Normalized Diluted EPS | 14.32% | 11.67% | -2.31% | -12.79% | -24.44% |
| Average Basic Shares Outstanding | 1.74% | 2.01% | 2.55% | 3.13% | 2.96% |
| Average Diluted Shares Outstanding | 1.74% | 2.01% | 2.55% | 3.13% | 2.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |